JonesTrading analyst Justin Walsh reiterated a Buy rating on Lantheus (LNTH – Research Report) today and set a price target of $120.00.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Justin Walsh’s rating is based on a combination of factors that highlight both challenges and opportunities for Lantheus Holdings. Despite the company’s recent earnings report showing a slight decline in net sales for PYLARIFY and a reduction in the full-year EPS guidance, Walsh sees potential for growth in the company’s radiopharmaceutical pipeline. The ongoing business reorganization, including acquisitions and divestitures, is expected to enhance operational efficiency and improve margins over the medium to long term.
Walsh acknowledges the competitive pressures and increased operating expenses due to recent acquisitions, which have contributed to a decrease in the price target from $134 to $120. However, he remains optimistic about the company’s strategic direction and execution capabilities. The anticipated completion of acquisitions and divestitures is expected to position Lantheus favorably in the market, justifying the Buy rating despite the current negative sentiment.
According to TipRanks, Walsh is an analyst with an average return of -3.8% and a 29.49% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Achieve Life Sciences, Theratechnologies, and Actinium Pharmaceuticals.
In another report released today, TD Cowen also maintained a Buy rating on the stock with a $110.00 price target.